The relationship between remission, non-specific structural cerebral pathologies, and atypical antipsychotic combination treatment in patients hospitalized with depression: a cross-sectional study

Mustafa Ugurlu, Gorkem Karakas Ugurlu and Ali Caykoylu

ABSTRACT

OBJECTIVE: The aim of this study was to determine the relationship between clinical variables related to patients hospitalized with depression.

METHODS: The files of patients hospitalized with depression were examined. Sociodemographic characteristics, clinical features and imaging reports were considered. Data for statistical analysis was obtained only from files that provided clear information.

RESULTS: The appropriate treatment for anxiety and psychotic symptoms had a significant effect on response in depression. The presence of non-specific structural cerebral pathologies had an important relationship with the length of hospitalization and suicidal ideation.

CONCLUSIONS: Depression is a disorder of which cause, course and outcome has been determined by several different factors. Therefore, addressing depression in a holistic manner is extremely important.

ARTICLE HISTORY

Received 14 November 2016
Accepted 27 February 2017

KEYWORDS

Anxiety; depression; mood disorders; suicide; treatment

Introduction

Depression is a common mental health problem that leads to significant disability and impaired quality of life [1–3]. The diagnosis is often complex, and there are issues in clinical practice that need to be clarified, including treatment, response and prognosis. However, research into depression has produced conflicting results. Therefore, there is a need for further research on the topic.

One cause of conflicting results is that the emergence, prognosis and treatment of depression are affected by many factors [4,5]. Other reasons include small sample sizes, sampling bias, measurement errors, incorrect interpretation of results and work on “sterile samples” (overly restricted samples that are unlike real life) [6].

The excessive focus is another research challenge. Excessive focus can be defined as considering only one aspect of the data set that was collected for the study. To benefit from all the data, the researcher should examine all possible meaningful relationships between variables in the data set, which will provide a deeper understanding of the issue under examination.

A review of the various studies in depressed patients presents us with a broader perspective. However, these reviews consist of different studies and consequently the results of different samples. However, all the features expressed in a review should be shown in the same patient sample. Therefore, the information provided by the review can be supported, and the importance of the review would be increased. For this purpose, we tried to understand what the data collected from patients hospitalized with depression could tell us. The main objective of this study was to obtain as much information as possible from the real-life data collected from patients hospitalized with depression and to examine the relationships between the information.

Methods

Study setting

This present study was conducted in the psychiatry clinic of a tertiary hospital. The hospital staff consisted of four nurses, four MD/psychiatry residents, one psychiatrist and three residents in training. The hospital maintained standard patent history files. A psychiatry resident made the initial assessment of the patient using the structured clinical interview for DSM-IV Axis I Disorders (SCID-I) [7,8]. The Hamilton Anxiety Scale (HAM-A), Hamilton Depression Rating Scale (HAM-D) and Brief Psychiatric Rating Scale (BPRS) were administered on admission (a) and discharge (d). Medical tests including routine laboratory tests, cranial magnetic resonance imaging (MRI) and electroencephalography (EEG) were performed during the hospital stay, and experts were consulted when necessary. This process continued as long as the...
patients stayed in the hospital until the missing data was completed.

The programme was not set up as a study or research project, but as a treatment programme and, all data analysed were collected as part of routine diagnosis and treatment of the patients. Therefore, we did not seek/obtain ethical approval for the study but rather study approval from the hospital’s administration. Also, depending on National Code on the Patient Rights (published on 1 August 1998), all patients must sign informed consents not only for specific trials but also for each medical application (diagnostic or therapeutic) in Turkey [9]. Therefore, a second consent has not been taken due to obtained initial informed consents. All researchers were trained on good clinical practice and declared that the presented study was in agreement with ethical standards outlined in the Declaration of Helsinki.

**Procedure**

The authors reviewed the files of patients admitted with depression diagnosis during the years 2012–2015. The data from patient files that were examined in the study were extracted as follows:

1. Files coded as F32–33 (depressive disorders) according to the World Health Organisation’s International Classification of Disease (ICD-10) [10] system were screened from the hospital archive.
2. Each file was assessed by one psychiatrist and one resident in training. A semi-structured form was used during the assessment. Sociodemographic data (age, gender and education level) and clinical characteristics from the SCID-I diagnosis (comorbidity, the age of onset, the number of previous episodes, the number of hospitalizations, the length of hospitalization, suicidal ideation, treatment characteristics, psychiatric or medical comorbidity, cranial MRI and EEG reports) were recorded on the form.
3. Non-specific structural cerebral pathology was determined in patients using the cranial MRI. Later, reports and consultation notes for these patients were examined. Patients who were assessed by a radiologist and neurologist as having non-specific structural change (atrophy, ischemic gliotic focus, lacunar infarct, and hyperintense areas) were grouped.
4. Treatment response to anxiety (Resp-A = HAMAa – HAMAd), treatment response to depression (Resp-D = HAMDa – HAMDd), treatment response to psychotic symptoms (Resp-P = BPSAs – BPSDd) and the remission variables (HAMDd ≤ 6 [11]) were calculated. The study protocol is summarized in Figure 1.

**Assessment tools**

Hamilton Anxiety Scale (HAM-A): HAM-A was one of the first rating scales to measure the severity of anxiety symptoms. It is still one of the most widely used rating scales and has been translated into Turkish [12–14]. It consists of 14 items that are assessed by the interviewer.

**Hamilton Rating Scale for Depression (HAM-D):** HAM-D is the standard measure of the severity of

![Figure 1. Schematic representation of the study method.](image-url)
depression, and is used to assess the effectiveness of the patient’s treatment. The scale has been translated into Turkish [15–17]. It consists of 17 items that are assessed by the interviewer.

**Brief Psychiatric Rating Scale (BPRS):** The BPRS is a useful instrument for measuring the severity of symptoms and change in symptoms for patients with depression [18]. It is also used for the measurement of psychotic symptoms in depressed patients [19].

**Inclusion and exclusion criteria**

**The inclusion criteria were:**

(a) at least two weeks of inpatient care,
(b) diagnosis of a major depressive disorder.

**The exclusion criteria were:**

(a) patients with any psychiatric diagnosis except anxiety disorder or major depressive disorder, for example, patients with bipolar or psychotic disorders,
(b) patients using a mood stabilizer,
(c) patients using an antipsychotic as monotherapy,
(d) patients with depressive disorder due to a general medical condition,
(e) patients with comorbid dementia,
(f) patients whose files contained incomplete data.

**Statistical analysis**

The distribution of variables was assessed with the Shapiro–Wilk test, and the statistical significance threshold was set as \( p < .05 \). To examine the relationship among all clinical variables, we used comprehensive statistical techniques, such as comparative statistics, correlation analysis, linear and logistic regression and path analysis. Variables that have significant differences in the comparative analysis or have a significant correlation were used in the regression and path analysis. In the path analysis, we examined how the clinical characteristics of major depression are associated with one another. Path analysis can be used to describe the effects of exogenous variables (treatment category or non-specific structural cerebral pathology) on endogenous (Resp-D or length of hospitalization) variables directly, indirectly, and by the sum of these variables. Path analysis enables an easy understanding of these effects by visualization in a path diagram. Exogenous variables in the model are those that are not explained by any variable. Endogenous variables in the model are those that are explained by exogenous variables or other endogenous variables (age of onset and Resp-P were both endogenous and exogenous variable in our study) [20,21]. Path analysis can predict that the equations system determines all causal links in a variables system, solves complex relationships between variables, and clearly reveals the strength of the relationship [22]. Suhr stated that if a path coefficient value is smaller than 0.10, there is the presence of a weak effect; if a path coefficient value is between 0.10 and 0.50, there is the presence of a moderate effect; if a path coefficient value is greater than 0.50, there is the presence of a strong effect [23].

**Results**

Of the 215 patient files that were examined in this study, 78 files were excluded, due to:

(1) diagnosis of bipolar disorder (9 files),
(2) psychotic disorder diagnosis (12 files),
(3) other comorbid psychiatric disorder (6 files),
(4) hospitalization of fewer than two weeks (31 files),
(5) mood stabilizer or antipsychotic as monotherapy (20 files),
(6) missing data (6 files).

The final data set contained 131 patient files.

The sociodemographic and clinical characteristics of the patients enrolled in the study were presented in **Table 1**. All modelling and path analysis was performed considering the correlations between variables, as presented in **Table 2**.

**Atypical antipsychotic combination and treatment response**

The number of patients in the antidepressant monotherapy group (A-M) was 41 (31.3%), and the number of patients receiving atypical antipsychotic combination therapy (AA-C) was 90 (68.7%). **Table 3** shows the variables that were significantly different in comparison between the treatment groups. There were no significant differences between other variables (for all pairwise comparisons, \( p < .05 \)). When performing logistic regression analysis, the only variable that determined inclusion in the combination therapy group was the BPRS score (\( R^2 = 0.144; \text{Wald (1)} = 7.692; \beta = 1.07; p = .006 \)). A one-unit increase in BPRS scores increased the possibility of receiving combination treatment by approximately 7%.

In path analyses, the treatment category did not appear to have a direct effect on the treatment response. However, it was found to have an indirect effect on treatment response in association with a reduction in BPRS score (**Figure 2**). Compared to the antidepressant monotherapy group, the patients receiving atypical antipsychotic combination therapy had a 27% increase in the Resp-P score. A one-unit increase in the Resp-P score was associated with a 62% increase in Resp-D score.
Suicidal ideation, length of hospitalization and non-specific structural cerebral pathologies

The variables affecting the length of hospitalization were tested by path analysis, and the age of onset, number of previous hospitalizations and HAM-A scores were found to be significantly important variables. The presence of non-specific structural cerebral pathology was found to be a significantly relevant variable that affected the age of onset (Figure 3).

Binary comparisons between the non-specific structural cerebral pathology group and the suicidal thought group \( \chi^2 (1) = 7.953; p = .005 \) and non-specific structural cerebral pathology group and medical comorbidity group \( \chi^2 (1) = 7.301; p = .007 \) showed a statistically significant difference. The presence of non-specific structural cerebral pathology reduced the risk of suicide by 48%. When grouping was performed according to the presence of suicidal ideation, the presence of non-specific structural cerebral pathology \( R^2 = 0.295; \text{Wald} (1) = 5.613; \beta = 0.324; p = .018 \) and the number of previous

| Table 1. Clinic and demographic characteristics of patients with major depression. |
|---------------------------------|-----------|---|
| Sex                             | Woman     | 86 | 65.6 |
| Education                       |           | 45 | 34.4 |
| Suicide ideation                | No        | 54 | 41.2 |
| Family history of psychiatric illness | No  | 65 | 49.6 |
| Medical comorbidity             | No        | 57 | 43.5 |
| Non-specific structural cerebral pathology | No  | 47 | 35.9 |
| Treatment category              | AA-C      | 90 | 68.7 |
| Remission                       | Remission | 33 | 25.2 |
| Non-remission                   |           | 98 | 74.8 |

| Table 2. Correlation between clinical characteristics. |
|---------------------------------|-----------|---|---|---|---|---|---|
|                        | Nn | Mean | SD | LoH | NoH | AoO | NoS |
| Sex                   |   |     |    |     |     |     |     |
| Woman                 | 86 | 65.6 |
| Man                   | 45 | 34.4 |
| Education             |   |     |    |     |     |     |     |
| Primary school        | 92 | 70.2 |
| High school and college | 39 | 29.8 |
| Suicide ideation      |   |     |    |     |     |     |     |
| No                    | 54 | 41.2 |
| Yes                   | 77 | 58.8 |
| Family history of psychiatric illness | No  | 65 | 49.6 |
| Yes                   | 66 | 50.4 |
| Medical comorbidity   |   |     |    |     |     |     |     |
| No                    | 57 | 43.5 |
| Yes                   | 74 | 56.5 |
| Non-specific structural cerebral pathology | No  | 47 | 35.9 |
| Yes                   | 46 | 35.1 |
| Treatment category    |   |     |    |     |     |     |     |
| AA-C                  | 90 | 68.7 |
| A-M                   | 41 | 31.3 |
| Remission             |   |     |    |     |     |     |     |
| Remission             | 33 | 25.2 |
| Non-remission         | 98 | 74.8 |

Note: AA-C, atypical antipsychotic + antidepressant combination; A-M, antidepressant monotherapy; BPRSa, Brief Psychiatric Rating Scale at admission; BPRSd, Brief Psychiatric Rating Scale at discharge; HAMMa, Hamilton Anxiety Scale Score at admission; HAMAd, Hamilton Anxiety Scale Score at discharge; HAMDa, Hamilton Depression Scale Score at admission; HAMDd, Hamilton Depression Scale Score at discharge; Resp-A, Treatment response for Anxiety (HAMAa - HAMAd); Resp-D, Treatment response for Depression (HAMDa - HAMDd); Resp-P, Treatment response for Psychotic Symptoms (BPRSa - BPRSd).

Suicidal ideation, length of hospitalization and non-specific structural cerebral pathologies

The variables affecting the length of hospitalization were tested by path analysis, and the age of onset, number of previous hospitalizations and HAM-A scores were found to be significantly important variables. The presence of non-specific structural cerebral pathology was found to be a significantly relevant variable that affected the age of onset (Figure 3).

Binary comparisons between the non-specific structural cerebral pathology group and the suicidal thought group \( \chi^2 (1) = 7.953; p = .005 \) and non-specific structural cerebral pathology group and medical comorbidity group \( \chi^2 (1) = 7.301; p = .007 \) showed a statistically significant difference. The presence of non-specific structural cerebral pathology reduced the risk of suicide by 48%. When grouping was performed according to the presence of suicidal ideation, the presence of non-specific structural cerebral pathology \( R^2 = 0.295; \text{Wald} (1) = 5.613; \beta = 0.324; p = .018 \) and the number of previous
suicide attempts (Wald (1) = 7.737; $\beta = 3.167; p = .005$) were found to be significantly important.

**Remission**

Binary logistic regression analysis was performed for the analysis of predictive factors for remission, and it was found that the increase in Resp-A score ($R^2 = 0.72$; Wald (1) = 16.026; $\beta = 2.529; p < .001$) and presence of suicidal ideation (Wald (1) = 4.850, $\beta = 0.103, p = .028$) were significantly important. While the presence of suicidal ideation reduced the likelihood of remission by about 90%, a one-unit increase in the Resp-A score increased the likelihood of remission by 2.5 times.

**Discussion**

In this study, the majority of patients had received a combination treatment. Adding an atypical antipsychotic to antidepressant treatment is common in the treatment of depression [24,25]. In treatment-resistant or severe cases of depression, the antipsychotic combination is the preferred method [26,27]. Psychotic and anxiety symptoms improved more in patients treated with atypical antipsychotics than in patients treated with antidepressant monotherapy, and this was consistent with other studies [28,29]. However, combination treatment did not have a significant direct effect on treatment response in depressive symptoms (Res-D). Figure 2 shows that the combination treatment had an indirect effect on depressive symptoms that was associated with a reduction in psychotic symptoms (Res-P). Other studies of patients with schizophrenia showed that atypical antipsychotics had antidepressant effects that indirectly reduced positive and negative symptoms, as well as a direct effect [30].

The current researchers believe that the length of hospitalization has been an indirect indicator of treatment resistance and severity of depression [31]. In this present study, pairwise comparison of atypical antipsychotic combination treatment vs. antidepressant monotherapy showed that the length of hospitalization was significantly longer for patients who received an atypical antipsychotic combination treatment (i.e. there was higher treatment resistance or disorder severity in this group). However, further analysis indicated that BPRS scores were a more specific factor.

Correlation analysis suggested that when anxiety and depression symptoms were increased, the length of hospitalization was also prolonged. Patch analysis showed that increasing age of onset, HAMAa [32] and the number of previous hospitalizations [33] were associated with an increased length of hospitalization. Other studies suggested that comorbid anxiety negatively affected prognosis and treatment response.

**Table 3. Comparison of treatment categories.**

| Treatment categories | n  | Mean | SD  | Med | Min | Max | $z$  | $p$     |
|----------------------|----|------|-----|-----|-----|-----|------|---------|
| BPRSa AA-C           | 90 | 27.7 | 9.5 | 28  | 6   | 60  | −3.572| <.001   |
| A-M                  | 41 | 22.1 | 8.3 | 22  | 6   | 53  | −2.102| .036    |
| Resp-A AA-C          | 90 | 13.4 | 6.2 | 13  | −1  | 31  | −2.102| .036    |
| A-M                  | 41 | 11.3 | 5.4 | 9   | 2   | 26  | −2.102| .036    |
| Resp-P AA-C          | 90 | 15.1 | 8.0 | 15  | −1  | 44  | −3.074| .002    |
| A-M                  | 41 | 10.5 | 6.4 | 9   | 0   | 26  | −1.962| .050    |
| LoH (day) AA-C       | 90 | 33.2 | 15.6| 29.5| 14  | 83  | −1.962| .050    |
| A-M                  | 41 | 27.3 | 10.7| 25  | 14  | 66  | −1.962| .050    |

Note: AA-C, atypical antipsychotic + antidepressant combination; A-M, antidepressant monotherapy; BPRSa, Brief Psychiatric Rating Scale at admission; LoH, length of hospitalization; Resp-A, treatment response for anxiety (HAMAa – HAMAd); Resp-P, treatment response for psychotic symptoms (BPRSa – BPRSd).
in depression [32,34]. Also, comorbid anxiety was also associated with initial depressive episodes and their recurrence [35]. The greater the number of depressive episodes, the worse becomes the prognosis of depression [36]. Poor prognosis and severe depression may prolong the length of hospitalization [37].

The advanced age of onset has been associated with recurrence [38], more severe depression, more anxiety, somatic symptoms [39] and treatment response [40]. Although the relationship between non-specific structural cerebral pathologies and the age of onset of depression have been shown before [41], the relationship between structural cerebral pathologies and depression is still controversial. A large body of published neuroimaging research into major depressive disorder has now identified several neuroanatomical changes in affected patients [42–44]. At first glance, it does not seem to be a major factor in the length of hospitalization, but there is an indirect relationship between the presence of non-specific structural cerebral pathology and the length of hospitalization.

A one-unit increase in the number of previous suicide attempts increased the risk of suicide ideation by 3.2 times. The number of previous suicide attempts is associated with an increased risk of suicide ideation [45]. Although white matter lesions [46], particularly structural abnormalities in the frontal area [47] and neurodegenerative changes [48] have been shown in patients who attempted suicide. Our study has shown that the presence of non-specific structural cerebral pathology was associated with a 32% decrease in the risk of suicidal ideation. Although it is hard to explain this with the biological effect of the non-specific structural cerebral pathology, it can be attributed to the fact that the patients with the non-specific structural cerebral pathology have more social support because of their poor general health status. Also, these patients were less exposed to the destructive effects of depression because depression was later in the onset of age. In this way, they can develop good social networks until the onset of the disease. Finally, due to poor health conditions, regular clinical follow-up can also be protective against suicide [49–51].

**Figure 3.** Factors affecting the length of hospitalization in patients with depression.
Finally, suicidal ideation and appropriate treatment of comorbid anxiety emerged as significant factors in remission. The relationship between suicidal ideation, multiple hospitalizations and the severity and recurrence of depression has been shown previously [52]. Independently of depression, anxiety increases the risk of suicidal ideation [53]. Furthermore, patients with greater pre-treatment anxiety took longer to respond to treatment, and had higher rates of recurrence [54,55], increased risk of withdrawal from treatment [56] and decreased response to acute antidepressant treatment [57].

The main limitation of our study is that it has a retrospective design, but to overcome this limitation, we used rigorous research criteria and robust information. Another limitation is that it does not include more details of the treatment because the patients were treated with medications in various dosages and different class. Therefore, we classified the treatment as antidepressant monotherapy and atypical antipsychotic combination.

As a result, successful treatment for anxiety and severity of anxiety symptoms appeared to be critical variables in patients with depression. Furthermore, the importance of atypical antipsychotics in combination with treatment response was again demonstrated, and it was shown that non-specific structural cerebral pathologies are important indirect variables in the prognosis and remission of depression. Depression is a disorder of which its cause, course and outcome are determined by many different factors.

Therefore, addressing depression in a holistic manner is extremely important. Figure 4, which shows the relationship between clinical variables in hospitalized patients with depression, provides a comprehensive understanding of depression and provides an example of this approach.

Acknowledgements

We would like to thanks Tugba Bulut who is a medical secretary for her kind work in patient archives.

Disclosure statement

No potential conflict of interest was reported by the authors.

References

[1] Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34:119–138.
[2] Wedegaertner F, Geyer S, te Wildt B, et al. Depression, anxiety and the risk of permanent disability and mortality in the working population in Germany: a cohort study. Eur Psychiatry. 1986;28:1.
[3] Angermeyer MC, Holzinger A, Matschinger H, et al. Depression and quality of life: results of a follow-up study. Int J Soc Psychiatry. 2002;48(3):189–199.
[4] Menard C, Hodes GE, Russo SJ. Pathogenesis of depression: insights from human and rodent studies. Neuroscience. 2016;321:138–162.
[5] Heim C, Binder EB. Current research trends in early life stress and depression: review of human studies.
on sensitive periods, gene-environment interactions, and epigenetics. Exp Neurol. 2012;233(1):102–111.

[6] Wardwell WI, Bahnsen CB. Problems encountered in behavioral science research in epidemiological studies. Am J Public Health Nations Health. 1964;54(6):972–981.

[7] First M, Spitzer R, Gibbon M, et al. Structured clinical interview for DSM-IV axis I (SCID-I), clinician version. Washington (DC): American Psychiatric Association; 1997.

[8] Corapcioğlu A, Aydemir O, Yıldız M, et al. Structured clinical interview for DSM-IV (SCID-I) Türkçe Formu. Ankara: Hekimlik Yayın Birliği; 1999.

[9] Kırça FS. Is ethics approval necessary for all trials? A clear but not certain process. Mol Imaging Radiancu Ther. 2013;22(3):73–75.

[10] WHO. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.

[11] Riedel M, Moller HJ, Obermeier M, et al. Response and remission criteria in major depression – a validation of current practice. J Psychiatr Res. 2010;44(15):1063–1068.

[12] Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–55.

[13] Thompson E. Hamilton rating scale for anxiety (HAM-A). Occup Med (Lond). 2015;65(7):601.

[14] Hamilton Anksiyete Derecelendirme Ölçeği (HDDÖ) nin geçerliliği ve geçerlilik çalışması, Date, 1998.

[15] Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr. 1960;23(1):56–62.

[16] Bagby RM, Byder AG, Schuller DR, et al. The Hamilton depression rating scale: Has the gold standard become a lead weight? Am J Psychiatry. 2004;161(12):2163–2177.

[17] Akdemir A, Örsel S, Dağ I, et al. Hamilton Depresyon Derecelendirme Ölçeği (HDDÖ)’nin geçerliliği, güvenilirliği ve klinikte kullanımı. Psikiyatri Psikoloji Psikofarmakoloji Dergisi. 1996;4(4):251–259.

[18] Zanello A, Berthoud L, Ventura J, et al. The brief psychiatric rating scale (version 4.0) factorial structure and its sensitivity in the treatment of outpatients with unipolar depression. Psychiatry Res. 2013;210(2):626–633.

[19] Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76(12):970–976.

[20] Oktay E, Akinci MM, Karaaslan A. Research on the interaction of statistics with the courses in business administration curriculum with using path analysis. J Graduate School Soc Sci. 2012;16(1).

[21] Şimşek Ö. Yapışal Eşlikli Uygulamalarına Giriş, Ekinoks Yayınları, Ankara: Elsevier; 2007.

[22] Lleras C. Path analysis. Encycl Soc Meas. 2005;3:25–30.

[23] Suhr D. Step your way through path analysis. Western Users of SAS Software Conference Proceedings; 2008.

[24] Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013;10(3):e1001403.

[25] Rogoz Z. Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: preclinical and clinical efficacy. Pharmacol Rep. 2013;65(6):1535–1544.

[26] Kasper S, Akimova E, Montgomery S. The role of atypical antipsychotics in inadequate-response and treatment-resistant depression. Treat Resistant Depression. 2013;70:107–128.

[27] Zhou X, Keitner GI, Qin B, et al. Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis. Int J Neuropsychopharmacol. 2015;18(11):ppy060.

[28] Gerhard T, Akincigil A, Correll CU, et al. National trends in second-generation antipsychotic augmentation for nonpsychotic depression. J Clin Psychiatry. 2014;75(5):490–497.

[29] Leadholm AKK, Rothschild AJ, Nolen WA, et al. The treatment of psychotic depression: is there consensus among guidelines and psychiatrists? J Affect Disord. 2013;145(2):214–220.

[30] Moller HJ. Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data. Eur Arch Psychiatry Clin Neurosci. 2005;255(2):83–93.

[31] Sitta P, Brand S, Schneider F, et al. Duration of inpatient depression treatment – fair benchmarking between hospitals. Psychother Psychosom Med Psychol. 2006;56(3–4):128–137.

[32] Goldberg D, Fawcett J. The importance of anxiety in both major depression and bipolar disorder. Depress Anxiety. 2012;29(6):471–478.

[33] Munley PH, Devone N, Einhorn CM, et al. Demographic and clinical characteristics as predictors of length of hospitalization and readmission. J Clin Psychol. 1977;33(4):1093–1099.

[34] Battenham PJ, Christensen H, Calear AL. Anxiety symptoms as precursors of major depression and suicidal ideas. Depress Anxiety. 2013;30(10):908–916.

[35] Wittchen H-U, Beesdo K, Bittner A, et al. Depressive episodes – evidence for a causal role of primary anxiety disorders? Eur Psychiatry. 2003;18(8):384–393.

[36] Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev. 2007;27(8):959–985.

[37] Barnow S, Linden M, Schaub RT. The impact of psychosocial and clinical variables on duration of inpatient treatment for depression. Soc Psychiatry Psychiatr Epidemiol. 1997;32(6):312–316.

[38] Gilman SE, Kawachi I, Fitzmaurice GM, et al. Socioeconomic status, family disruption and residential stability in childhood: relation to onset, recurrence and remission of major depression. Psychol Med. 2003;33(8):1341–1355.

[39] Gournellis R, Oulis P, Rizos E, et al. Clinical correlates of age of onset in psychotic depression. Arch Gerontol Geriatr. 2011;52(1):94–98.

[40] Gudayol-Ferre E, Guárdia-Olmos J, Peró-Cebollero M, et al. Prediction of the time-course pattern of remission in depression by using clinical, neuropsychological, and genetic variables. J Affect Disord. 2013;150(3):1082–1090.

[41] Sexton CE, Mackay CE, Ebmeier KP. A systematic review and meta-analysis of magnetic resonance imaging studies in late-life depression. Am J Geriatr Psychiatry. 2013;21(2):184–195.

[42] Jellinger KA. Organic bases of late-life depression: a critical update. J Neural Transm. 2013;120(7):1109–1125.

[43] Xekardaki A, Santos M, Hof P, et al. Neuropathological substrates and structural changes in late-life depression: the impact of vascular burden. Acta Neuropathol. 2012;124(4):453–464.
[44] Lorenzetti V, Allen NB, Fornito A, et al. Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies. J Affect Disord. 2009;117(1–2):1–17.

[45] Schmitt A, Falkai P. Suicide ideation, stability of symptoms and effects of aerobic exercise in major depression. Eur Arch Psychiatry Clin Neurosci. 2014;264(7):555–556.

[46] Sachs-Ericsson N, Hames JL, Joiner TE, et al. Differences between suicide attempters and nonattempters in depressed older patients: depression severity, white-matter lesions, and cognitive functioning. Am J Geriatr Psychiatry. 2014;22(1):75–85.

[47] Lippard ETC, Johnston JAY, Blumberg HP. Neurobiological risk factors for suicide: insights from brain imaging. Am J Prev Med. 2014;47(3, Supplement 2):S152–S562.

[48] Peisah C, Snowdon J, Kril J, et al. Clinicopathological findings of suicide in the elderly: three cases. Suicide Life Threat Behav. 2007;37(6):648–658.

[49] Uchino BN. Social support and health: a review of physiological processes potentially underlying links to disease outcomes. J Behav Med. 2006;29(4):377–387.

[50] McLean J, Maxwell M, Platt S, et al. Risk and protective factors for suicide and suicidal behaviour: a literature review. Edinburgh: Scottish Government; 2008.

[51] Office of the Surgeon G, National Action Alliance for Suicide P. Publications and Reports of the Surgeon General. 2012 national strategy for suicide prevention: goals and objectives for action: a report of the US surgeon general and of the national action alliance for suicide prevention. Washington (DC): US Department of Health & Human Services (US); 2012.

[52] Mirsu-Paun A. Exploratory path models regarding the associations between suicide ideation, depression, interpersonal difficulties, and self-esteem among young adults. Eur Psychiatry. 30(Supplement 1):959.

[53] Thibodeau MA, Welch PG, Sareen J, et al. Anxiety disorders are independently associated with suicide ideation and attempts: propensity score matching in two epidemiological samples. Depress Anxiety. 2013;30(10):947–954.

[54] Andreescu C, Lenze EJ, Dew MA, et al. Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study. Br J Psychiatry. 2007;190(4):344–349.

[55] Alexopoulos GS, Katz IR, Bruce ML, et al. Remission in depressed geriatric primary care patients: a report from the PROSPECT study. Am J Psychiatry. 2005;162(4):718–724.

[56] Flint AJ, Rifat SL. Anxious depression in elderly patients. Response to antidepressant treatment. Am J Geriatr Psychiatry. 1997;5(2):107–115.

[57] Steffens DC, McQuoid DR. Impact of symptoms of generalized anxiety disorder on the course of late-life depression. Am J Geriatr Psychiatry. 2005;13(1):40–47.